首页> 外文期刊>Human Molecular Genetics >Association analysis of functional variants of the FcgRIIa and FcgRIIIa genes with type 1 diabetes, celiac disease and rheumatoid arthritis.
【24h】

Association analysis of functional variants of the FcgRIIa and FcgRIIIa genes with type 1 diabetes, celiac disease and rheumatoid arthritis.

机译:FcgRIIa和FcgRIIIa基因的功能变异与1型糖尿病,腹腔疾病和类风湿关节炎的关联分析。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

FcgRIIa and FcgRIIIa are potent modulators of the immune system which bind (auto)antibodies and activate immune cells. The FcgRIIa*A519G and FcgRIIIa*A559C functional variants have been associated with several immune-related diseases. We studied FcgRIIa*A519G and FcgRIIIa*A559C SNPs in type 1 diabetes (T1D), celiac disease (CD) and rheumatoid arthritis (RA) patients and controls and included a meta-analysis of all recent studies of FcgRIIIa*A559C and RA. Our cohorts comprised 350 T1D, 519 CD, 639 RA patients and 1359 controls, who were genotyped for FcgRIIa*A519G and FcgRIIIa*A559C variants. Regression and expectation maximization (EM) algorithm-based haplotype analyses were used for the data analysis. We found significant differences in genotype frequencies of FcgRIIa between controls and patients with T1D (P = 0.04), CD (P = 0.000005) and RA (P = 0.04). The FcgRIIa*519GG genotype showed an increased risk for both T1D [odds ratio (OR) = 1.51; 95% confidence interval (95% CI) 1.08-2.12; P = 0.015] and CD (OR = 1.81; 95% CI 1.35-2.37; P = 0.000004), but not for RA. There was no difference in the frequency of FcgRIIIa*A559C genotypes or allelotypes between controls with T1D, CD and RA. We found that FcgRIIa and FcgRIIIa haplotype frequencies differed significantly between controls and patients with T1D (P = 0.05) and with CD (P = 0.00038) but not with RA. Our meta-analysis showed a significant 1.37(95% CI 1.14-1.66)-fold increased risk of RA for the FcgRIIIa*559CC (158VV) genotype (P = 0.001). This is the first report that the FcgRIIa*519GG genotype predisposes to T1D and CD. We confirmed that the FcgRIIIa*559CC genotype is associated with RA. If replicated, our findings would suggest FcgRIIa*519G as a common risk factor for auto-immune diseases. This may have clinical implications with regard to efficacy or safety of antibody-based immuno-modulator therapies.
机译:FcgRIIa和FcgRIIIa是结合(自身)抗体并激活免疫细胞的免疫系统的有效调节剂。 FcgRIIa * A519G和FcgRIIIa * A559C功能变体与几种免疫相关疾病有关。我们在1型糖尿病(T1D),乳糜泻(CD)和类风湿性关节炎(RA)患者和对照中研究了FcgRIIa * A519G和FcgRIIIa * A559C SNP,并包括对FcgRIIIa * A559C和RA的所有近期研究的荟萃分析。我们的队列包括350名T1D,519名CD,639名RA患者和1359名对照,他们均针对FcgRIIa * A519G和FcgRIIIa * A559C变体进行了基因分型。基于回归和期望最大化(EM)算法的单倍型分析用于数据分析。我们发现对照组和患有T1D(P = 0.04),CD(P = 0.000005)和RA(P = 0.04)的患者之间FcgRIIa的基因型频率存在显着差异。 FcgRIIa * 519GG基因型显示两种T1D的风险均增加[几率(OR)= 1.51; 95%置信区间(95%CI)1.08-2.12; P = 0.015]和CD(OR = 1.81; 95%CI 1.35-2.37; P = 0.000004),但对于RA没有。在患有T1D,CD和RA的对照之间,FcgRIIIa * A559C基因型或等位基因的频率没有差异。我们发现FcgRIIa和FcgRIIIa单倍型频率在对照组和T1D患者(P = 0.05)和CD患者(P = 0.00038)与RA患者之间没有显着差异。我们的荟萃分析显示,FcgRIIIa * 559CC(158VV)基因型的RA风险显着增加1.37(95%CI 1.14-1.66)倍(P = 0.001)。这是FcgRIIa * 519GG基因型易患T1D和CD的第一个报道。我们证实FcgRIIIa * 559CC基因型与RA相关。如果复制,我们的发现将提示FcgRIIa * 519G是自身免疫疾病的常见危险因素。这可能对基于抗体的免疫调节剂疗法的功效或安全性具有临床意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号